Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon’s COVID-19 Drug FYB207
Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Meet your New Colleagues
Formycon’s employees are the foundation of our success. We strongly believe that an appreciative corporate culture contributes significantly to our progress. Therefore, we cultivate a culture of diversity and mutual appreciation.
We offer you the opportunity for rapid career advancement in a dynamic, high-growth environment where professionalism and team spirit form the foundation of our daily cooperation.